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Patient acceptability of targeted risk-based
detection of non-communicable diseases in
a dental and pharmacy setting
Zehra Yonel1* , Asma Yahyouche2, Zahra Jalal2, Alistair James1, Thomas Dietrich1 and Iain L. C. Chapple1
Abstract
Background: Non-communicable diseases [NCDs] are the major cause of mortality globally and are increasing in
prevalence. Different healthcare professionals’ access different population groups; and engaging allied healthcare
professionals in risk-driven early case detection of certain NCDs may be beneficial, especially those who have not
been tested for NCDs within the previous 12 months.
The objectives of this study were to determine: whether NCD case finding in dental/community pharmacy settings
is feasible in terms of patient acceptability, barriers to recruitment, impact on the existing service. Determine time
taken to test for: type 2 diabetes risk [T2DM], chronic obstructive pulmonary disease [COPD], hypertension, vitamin
D deficiency and chronic kidney disease [CKD]. Determine whether there is added benefit of point of care testing
[POCT] to identify diabetes risk compared to a validated screening questionnaire alone.
Methods: An exploratory study was undertaken to explore issues associated with NCD assessment in one dental
practice and one community pharmacy within the West-Midlands, UK. Fifty patients > 40 years-of-age were
recruited per site. Participants undertook: a questionnaire providing demographic data, any previous NCD diagnosis
or positive family history. Validated questionnaires for determining NCD risk [T2DM/COPD]. Chair-side capillary
blood [finger-prick] samples for HbA1C, creatinine/eGFR, Vitamin-D.
Prior work had been undertaken to measure the agreement between point of care testing [POCT] devices and a
central laboratory method, and to gauge the opinions of participants regarding discomfort experienced using
venous (antecubital fossa) and capillary (finger-prick) blood collection, via a 10 cm Visual-Analogue-Scale. The POCT
devices demonstrated good concordance with laboratory testing and were acceptable methods of blood collection
for participants.
Results: Recruitment rates demonstrated that 8 days were needed to recruit 50 participants and 60% of those
approached opted to participate. The principal barrier to participation was time, with average time taken to test
being 19mins. Utilising dental and pharmacy settings identified potential cases of previously undiagnosed disease.
Conclusions: Risk-targeted testing for NCDs in high street dental and community pharmacies is both attractive and
acceptable to patients.
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Background
The prevalence of chronic non-communicable diseases
[NCDs] is increasing and their impact on the global
disease burden and healthcare economy is substantial.
Evidence in 2015 suggested that 92% of older adults have
at least one NCD and 77% have two NCDs [1]. The
reason for the increasing prevalence of NCDs is, in part,
the result of an ageing population, and also due to an
increase in the prevalence of risk-factors common
amongst most NCDs such as sedentary lifestyles, refined
diets and overweight/obesity. In addition to the substan-
tial health burden, risk-factors for NCDs also contribute
a significant economic burden, accounting for over 45%
of total NHS costs in the UK in 2006–2007, at approxi-
mately £43-billion [2].
Allied healthcare professionals in the UK access large
proportions of the population who frequently do not
access general medical practice [GP] services [3]. Given
the growing NCD burden, this study aimed to determine
patient acceptability and potential barriers to utilising
allied healthcare professionals such as dentists and
pharmacists in order to assist GPs with the NCD
epidemic, through targeted risk-based assessment and
early detection.
Rationale for risk directed early NCD detection in dental
practice and community pharmacy settings
Dental
Members of the public usually only attend their GP
when they are unwell, whereas, many people routinely
visit their dentists on a regular (6–12 monthly) basis,
thus facilitating prevention and lifestyle interventions
[4]. Evidence from the USA suggests that, in 2008, 24%
of people did not have contact with a general healthcare
provider, yet 23% of those accessed a dentist during that
time [5]. This was also reported for a UK population,
where 12% of patients who reported seeing a dentist bi-
annually reported they had not had contact with a GP in
the same 12-month period [3]. Furthermore, 48% of
those who reported being regular dental attenders
advised having never had a health check at their GP sur-
gery [3]. With approximately 60% of the UK population
registered with a dentist [6], this places dental teams,
with access to patients who would not necessarily attend
their GP regularly, in an ideal position to target patients
for risk assessments.
Pharmacy
The 2011 Pharmaceutical Group of the European Union
survey reported that 98% of European patients can reach
their nearest community pharmacy within 30min, while
58% indicated that their closest community pharmacy
was within 5 min of their home. This may render phar-
macy settings ideal for early identification of NCDs and
provision of preventative advice for large population
groups, who may not routinely have access to other
healthcare professionals. In addition, over the past four
decades there has been a move in pharmacy practice
away from the traditional focus on dispensing towards a
more patient-centred clinical role [7]. United Kingdom
[UK] policy and pharmacists’ professional organisations
have stressed the potential of community pharmacists to
extend their roles in patient care services to include
screening for NCDs. This has been emphasised in policy
papers calling for a wider use of community pharmacists
in primary patient care [8–10].
Inter-professional collaboration
The development of government policies and guidelines
advocating the role of allied healthcare professionals in
risk-assessment, prevention programs and risk identifica-
tion for NCDs, suggests that a collaborative approach to
tackle the growing NCD burden is required [11]. It is
currently common for dentists to liaise with GPs in rela-
tion to medications a patient may be taking, especially
where these may have an impact on oral health, such as
calcium channel blockers which may result in gingival
overgrowth. Dentists also work closely with a patient’s
medical team when the dentist suspects underlying
conditions based on the oral manifestations of systemic
diseases. One such example is poorly controlled type 2
diabetes [T2DM]. T2DM may present with oral signs
and symptoms including multiple lateral periodontal ab-
scesses. Recently the International Diabetes Federation
and European Federation of Periodontology produced
joint guidelines for medical and dental professionals for
the effective management of patients with periodontitis
and, or T2DM in recognition of the strong associations
between oral and systemic health [12].
Community pharmacists play an important role in
delivering public health services for example vaccina-
tions, health checks, smoking cessation and weight
management to complement GP roles. In addition to
pharmacist role in optimising the use of medicines in li-
aison with GPs, providing advice about safe and effective
use of medicines when dispensing to patients with
prescriptions for the treatment of diabetes, heart disease
and hypertension and thus relieving the pressure on the
GP practices and A&E. Furthermore, pharmacists work
directly in general practice as part of the multi-
disciplinary team, in patient facing roles when managing
conditions such as diabetes and hypertension [13]. A re-
cent systematic review and meta-analysis which included
21 RCTs (8933 patients) showed that pharmacists-led in-
terventions, as part of a team in general practice, can
significantly reduce medical risk factors of CVD events
when managing patients with hypertension, diabetes and
dyslipidaemia [14].
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Risk-assessments
Risk-assessment strategies need to ideally provide high
sensitivity and specificity so we can discriminate be-
tween those who truly do and do not have the condition,
be acceptable to patients undergoing assessment, accept-
able to the professional delivering the assessment and
also demonstrate cost-effectiveness. Venous blood sam-
ples are often considered the “gold-standard” testing
method for diagnosing many NCDs. The feasibility of
primary care dental teams and community pharmacies
undertaking venous blood sampling to assess for NCDs
is low – as this is not within their routine scope of prac-
tice, in addition to the time and resources required to
test in this way. Alternative methods for undertaking
risk-assessments were considered in this study including
the use of validated risk-assessment questionnaires and
point-of-care testing [POCT] devices.
Validated questionnaires may be effective ways of
stratifying the population into risk groups to allow more
invasive and costly tests to be targeted to those in the
population most in need. Though, the identification of
“at risk” individuals with risk-assessment questionnaires
are often satisfactory they often have lower sensitivity
and specificity than conventional testing methods. But
this has to be weighed up against the advantages of ease
of testing, patient acceptability and relatively low associ-
ated costs. Given that the aims of risk-assessment in
primary care dental and pharmacy settings are not to
formally diagnose but to indicate those who may be at
elevated risk, the reduction in accuracy may be accept-
able given the aforementioned advantages.
POCT remains controversial due to the historical
challenges associated with a wide range of devices avail-
able, each with their own advantages, disadvantages and
varying levels of accuracy [15, 16]. However, the
improved quality of POCT devices for capillary blood
sampling has resulted more recently in NICE and other
national bodies recommending their use for diagnosis of
certain NCDs [15, 17–20]. Given that we are not pro-
posing primary care dental teams and community phar-
macists formally diagnose, but instead identify those
who may be at risk and require further management,
they may be ideal for the purpose of risk-assessment in
primary care and community settings. The relative ease
of use, the near immediate results and the reported pa-
tient satisfaction related to POCT are also advantageous.
However, it is important that practitioners are aware of
the limitations associated with their specific device and
the cost associated with these devices may be higher
than conventional testing methods.
Patient acceptability of undertaking targeted risk-based
detection for NCDs in UK dental and pharmacy settings
is currently unknown and requires further investigation.
Therefore, an exploratory study was undertaken within
one dental practice and one community pharmacy
within the West-Midlands, UK, to determine patient
acceptability of risk-assessment for NCDs in these
settings.
Aims and objectives
The overarching aim of this study was to assess patient
acceptability of screening for NCDs in a primary dental
care and a community pharmacy setting. Further objec-
tives of the study included:
1. To identify whether testing for NCDs in a high
street dental practice and a community pharmacy
setting was feasible in terms of logistics,
environment and process. Including feasibility of
participant recruitment and barriers to recruitment.
2. To determine whether there is benefit to the finger
prick HbA1C test to identify diabetes risk compared
to a validated screening questionnaire alone.
3. To ascertain changes needed in the study protocol
and barriers to a larger scale study.
4. To determine whether any patients potentially at
high-risk of NCDs could be identified where disease
status was previously unknown.
Methods
One dental practice serving both National Health Ser-
vice (NHS) patients and private patients was selected for
participation in the study. Only those patients attending
the practice for provision of NHS dental services were
approached for participation in the study. The dental
practice was situated in the West Midlands, as was the
Community Pharmacy. Screening was undertaken for 50
consecutive patients recruited at each site.
Patients over 40 years of age were given a patient in-
formation leaflet (PIL) and consented to participate in
the study, and a member of the research team conducted
the screening as per the standard operating protocol
(SOP) (Additional file 1: Appendix 1). A recruitment log
was completed, as was any reason cited for non-
participation. Time taken to complete the process from
consent to completion was also recorded. Participants
completed a questionnaire outlining demographic data
and previous diagnosis and family history of NCDs.
Upon completion of the risk-assessment process partici-
pants were also asked to provide feedback or additional
comments related to the risk-assessment process
(Additional file 1: Appendix 2).
Validated risk-assessment questionnaires were under-
taken for determining participants’ risk of T2DM [21]
and chronic obstructive pulmonary disease [COPD] [22].
The “Diabetes Risk Score” developed by Leicester
University and Diabetes UK is a validated tool recom-
mended by NICE. The risk-assessment consists of seven
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questions giving a score between 0 and 47. Depending
on the patients total score they are categorised into one
of four groups: low risk, increased risk, moderate risk or
high risk. The risk assessment gives both the current risk
of having undiagnosed T2DM, but also a 10 year risk of
developing the condition [21]. The COPD risk score
“Drive4COPD” is also a validated tool. This risk-
assessment consists of five questions resulting in a score
from 0 to 10. Depending on the total score awarded
patients are then categorised into one of two groups
those with a total score that is greater than or equal to 5
or those with a score less than 5 [22].
POCTs to ascertain the presence or absence of risk-
factors for the following NCDs: T2DM (HbA1c capillary
blood sample), hypertension, atrial fibrillation [AF],
height and weight (BMI calculation) - as surrogate
markers for cardiovascular disease [CVD], chronic
kidney disease [CKD] (creatinine and eGFR capillary
blood sample) and Vitamin-D deficiency (capillary blood
sample).
Inclusion and exclusion criteria
Inclusion criteria
1. Be able to provide informed consent to participate
in the trial
2. Patients aged ≥40 years
3. treatment via NHS services
Exclusion criteria
1. Not meeting the inclusion criteria or
2. Not amenable to proposed testing method i.e.
finger-prick testing.
3. Solely private patients
As part of screening the participant undertook:
1. A questionnaire to provide basic demographic data
and to ascertain any previous diagnosis of any of
the NCDs, or a positive family history of any of the
NCDs. (Additional file 1: Appendix 2)
2. A validated questionnaire to determine risk of
COPD [Drive4COPD] [22].
3. A validated questionnaire for risk of diabetes
[Leicester Risk Assessment Tool, Diabetes Know
your risk] [21].
4. Blood pressure, pulse and AF monitoring using the
National Institute for health and Care Excellence
[NICE] approved WatchBP device.
5. A chair-side finger-prick sample to assess HbA1C
concentration/levels [Siemens/Bayer DCA Vantage]
6. A chair-side finger-prick sample to assess eGFR
[Nova StatSensor]
7. A chair-side finger-prick sample to assess vitamin-D
levels [Cityassays.org.uk]
Two methods were utilised to risk assess for non-
diabetic hyperglycaemia (NDH) and T2DM. The “Leices-
ter Risk-Assessment” questionnaire [LRA] tool, which is
validated and recommended by NICE and Diabetes UK;
and a point-of care HbA1c test (DCA-Vantage,
Siemens).
All analyses were performed by trained members of
the research team and the logistics and time involved
recorded alongside patient feedback.
Initial data was analysed to establish answers to the
research questions. Accepted reference values were used
based on current UK guidelines for each of the specific
conditions assessed.
Recruitment process
In each setting a consecutive sampling approach was
adopted with potential participants identified by a
member of the study team who applied the inclusion/
exclusion criteria and if eligible, written informed
consent for their participation in the trial was obtained.
Recruitment continued until the recruitment target of
50 participants was met, refusal rate was recorded and if
participant was willing to disclose reason for refusal this
too was documented.
Those participants for whom an abnormal finding or
presumptive diagnosis was identified were advised to
visit their GP and a follow-up letter was forwarded to
their GP, with participant consent. Only if the partici-
pant did not provide consent for their GP to be con-
tacted was a general letter with their results of interest
provided to the participant such that they could present
it to their GP at a later date should they so desire.
Statistical analysis plan
Descriptive statistics were used to analyse the study find-
ings. Data on the recruitment to the study was also
analysed descriptively, including the number of patients
approached, the number that agreed to participate and
number eligible to participate. Reasons for non-entry
into the study were assessed. Reasons for non-
completion were also analysed descriptively.
No formal sample size calculation was undertaken for
this study. The sample size (n = 50, in each site) was
deemed sufficient to enable identification of practical
challenges involved with running such a study in a den-
tal and pharmacy setting and allowed identification of
areas where change is required prior to implementing
such a model on a larger scale. The intention of this
phase of the study was to identify barriers to conducting
a similar style study using a larger sample within mul-
tiple primary care dental practices and pharmacies,
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across a broader geographical area. This study was not
powered to detect new cases of disease.
Results
Table 1 demonstrates that the study was balanced for
males and females in both settings. There was a spread
across each of the age categories with the average age of
participants in dental settings being younger than those
recruited in pharmacy settings, with a mean age of 58
years and 65 years respectively. In the dental setting all
participants identified themselves as white/Caucasian
and in the pharmacy setting all but 1 participant identi-
fied themselves as white/Caucasian. Most participants
reported themselves to be retired with the second high-
est category being professionals in both settings. There
were approximately three times as many professionals in
the dental setting compared to the pharmacy setting (32:
11) and more participants in the pharmacy setting con-
sidered themselves to be in manual or non-manual work.
In both dental and pharmacy settings about half of par-
ticipants considered themselves non-smokers who had
never smoked (52% & 51% respectively) (Additional file
1: Appendix 3), with approximately a third of partici-
pants reporting being previous smokers (38% & 32%
respectively) in both settings (Table 1).
Recruitment and impact on existing service
There was a 60% conversion rate in the dental setting
and the recruitment target of 50 participants achieved in
8 days. Recruitment in the pharmacy setting showed a
59% conversion rate and the recruitment target of 50
participants achieved in 14 days. The main reason cited
for declined participation in both settings was time. In
addition to being the major barrier to recruitment, time
was also the major consideration when determining
impact on existing services. The average time taken for
case-detection in both settings was 19mins.
Demographic data
The most common age category sampled within the
dental setting were participants between the ages of 50–
59 years followed by the 60–69 years category. The mean
age was 58 years with the oldest participant being aged
89 years and the youngest aged 41 years. The most com-
mon age category sampled within the pharmacy setting
were participants aged 70+ years followed by the 60–69
years category. The mean age was 65 years with the old-
est participant being aged 83 years and the youngest par-
ticipant aged 40 years.
Female participants made up 47% of the dental sample
and all participants in the dental setting identified their
ethnicity as white/Caucasian. 44% of volunteers were re-
tired, 32% considered themselves to be a professional,
14% were manual workers, 2% were non-manual
workers and 8% considered themselves to be executive/
managerial workers (Table 1). Female participants made
up 53% of the pharmacy sample and all participants ex-
cept 1 in the pharmacy setting identified themselves to
be White/Caucasian ethnicity. 61% of patients were re-
tired, 11% considered themselves to be a professional,
10% were manual workers, 10% were non-manual
workers and 4% considered themselves to be executive/
managerial workers (Table 1).
Diabetes
In the dental setting of 45 patients without an existing
diagnosis of diabetes, 21 (47%) rated high-risk on the
LRA, the recommendation for which is GP referral. Of
these 2 (4.4%) had an HbA1c in the diabetes range (> 48
mmol/mol). A further 7 (16%) had scores 42-48 mmol/
mol (NDH). However, 12/21 who were highlighted as in
need of referral to a GP according to the LRA, actually
had a HbA1C within the healthy reference range (< 42
mmol/mol) (Fig. 1a and b).
In the pharmacy setting of 44 patients without an
existing diagnosis of diabetes, 13 (30%) rated high-risk
on the LRA, with a further 13 (30%) rated moderate risk,
the recommendation for which is GP referral. Of these,
4 had an HbA1c in the diabetes range (> 48mmol/mol)
A further 7 had scores between 42 and 48mmol/mol
(NDH). In the pharmacy setting a total of 26 participants
were highlighted as needing referral to GP according to
the LRA, with only 11 having a HbA1C greater than 42
mmol/mol according to the POCT. One participant who
had a finger prick HbA1c in the NDH range was flagged
in the increased risk category (which according to the
Table 1 Summarising demographic data of participants
recruited from dental and pharmacy settings
Dental Pharmacy
Number recruited (N) 50 51
Time taken to recruit (days) 8 14
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LRA does not require referral to GP but advises lifestyle
changes to be made).
CVD
In the dental setting 34% of participants were deemed to
be overweight based on their BMI with a further 28%
having a BMI greater than 30 classifying them as obese.
Of those who stated they did not believe themselves to
have CVD or hypertension, 17 (44%) had an elevated
systolic reading (> 140 mmHg) and 13% had a diastolic
reading > 100 mmHg.
In the pharmacy setting 47% of participants were
deemed to be overweight based on their BMI with a
further 25% having a BMI greater than 30 classifying
them as obese. Of the 26 participants who stated they
did not believe themselves to have CVD or hypertension,
9 (41%) had an elevated systolic reading (> 140 mmHg)
and 35% had a diastolic reading > 100 mmHg.
CKD
Only one participant in the dental setting stated they
had known chronic kidney disease when asked. Al-
though most participants had an estimated glomerular
filtration rate (eGFR) > 90, 11 participants had an eGFR
of 89–60 (stage 2 kidney disease) and a further 4 had an
eGFR of between 55 and 49 (stage 3a kidney disease).
a
b
Fig. 1 a Flow diagram showing risk-assessment process for undiagnosed T2DM and benefit of 2-stage process in dental setting. b 2 × 2 diagram
showing risk-assessment process for undiagnosed T2DM and benefit of 2-stage process in dental setting
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Only one participant in the pharmacy setting stated
they had known chronic kidney disease when asked. Yet,
although 16 participants had an eGFR > 90, 19 partici-
pants had an eGFR of 89–60 and a further 6 had an
eGFR of between 55 and 49.
COPD
Two participants in the dental setting reported knowing
they had COPD. In addition to correctly identifying
those 2 participants the COPD risk assessment tool also
highlighted a further 2 participants in the dental setting
who may be at increased risk of COPD.
The COPD risk assessment tool identified 7 people
who may be at increased risk of COPD in the pharmacy
setting. Three participants in the pharmacy setting re-
ported knowing they had COPD, of which 1 participant
was picked up by the risk assessment tool as being high
risk while the other 2 were missed. A further 6 partici-
pants who thought themselves not to have COPD were
identified by the risk assessment tool as being high risk
and in need of referral to a GP.
Vitamin D
In the dental setting 8 participants were highlighted as
having insufficient vitamin D levels, none of whom were
aware of having vitamin D insufficiency. Of the three
participants who reported thinking they were deficient
in vitamin D, all had results within the healthy reference
value.
In the pharmacy setting 7 participants were
highlighted as having insufficient vitamin D (30.1-50
nmol/L) and a further 2 were deficient (15-30 nmol/L),
none of whom were aware of having vitamin D insuffi-
ciency/deficiency. Of the 2 participants who reported
thinking they were deficient in vitamin D, all had results
within the healthy reference range.
Patient acceptability
Of those subjects who participated acceptability and
satisfaction was very positive with only 3 participants
providing neutral or negative feedback (Additional file 1:
Appendix 4). Of those patients who declined participa-
tion no additional feedback was received except for
reason for refusal, the most common being a lack of
time.
Discussion
This overarching aim of this study was to assess patient
acceptability of screening for NCDs in primary care den-
tal practices and community pharmacy settings, with a
view to determine practical challenges and barriers
relating to logistics, environment and process, whether
there was benefit to POCT testing HbA1c in addition to
risk-assessment tool alone and to ascertain barriers to a
larger scale study. A further objective was to determine
whether potentially high-risk of NCDs could be identi-
fied within these settings where individual risk or disease
status was previously unknown.
Recruitment rates were better in a dental setting with
half the amount of time required to reach the recruit-
ment target of 50 participants. However, the time take
to recruit participants in both settings was satisfactory
with no obvious recruitment challenges experienced by
the study team. However, it must be noted that although
the participants enrolled in the study were of a range of
ages and a satisfactory gender balance. The study partici-
pants were not representative of the general population
of the West Midlands in terms of ethnic identity. Thus
it remains to be determined whether recruitment of in-
dividual’s from ethnic backgrounds known to be associ-
ated with increased risk of these specific NCDs is
achievable based on the results of this study.
The demographic data for patients in both the dental
and pharmacy settings were comparable although more
people identified themselves as professionals within the
dental than the pharmacy setting. In both the dental and
pharmacy setting the patient satisfaction and acceptabil-
ity was high. Participants found the method of testing
acceptable and participant feedback relating to testing
for NCDs in both dental and pharmacy settings was
positive (Table 2).
The main reason cited for non-participation in both
settings was lack of time. The average time taken to test
in both settings was 19mins. Where an additional
member of staff was not available to undertake risk-
assessment the potential impact on routine activities in
both settings would be significant with increased delays.
In the dental setting patients arriving for appointments
often attended the practice in advance of the scheduled
appointment time, thus could be offered a risk assess-
ment prior to seeing the dental team or could be offered
a risk-assessment immediately upon completion of their
dental appointment. In this particular practice there was
a spare surgery available for the risk-assessment to take
place. However, where an additional room was not
available increased waiting time and potential delays to
risk-assessments or scheduled dental activity may pose
an additional barrier. The key finding relating to impact
on current service was therefore for risk-assessment to
be undertaken effectively an additional member of dedi-
cated staff would be required to undertake testing and
an additional room dedicated to the risk-assessment
process.
The benefit of undertaking a two-step risk-assessment
process for identifying potential T2DM was shown to be
beneficial in improving the specificity of the T2DM risk-
assessment (Fig. 1a). When questionnaire based risk-
assessment alone was used it resulted in potentially 90%
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more referrals to GP than when a two-step risk assess-
ment process was utilised. Clearly given how busy GP
colleagues are and the time burden they are already
under caring for patients, it is important that their time
is protected and not taken up by inappropriate, unneces-
sary referrals. Thus a two-stage risk-assessment would
appear preferable, however a full economic evaluation
comparing these methods has not been undertaken.
The risk-assessment methods used appeared to iden-
tify people at high risk of NCDs who were previously
undiagnosed and unaware of their risk status. Potential
cases of previously undiagnosed disease were identified
in both dental and pharmacy settings. This is despite the
fact that the demographic of the study population
predominantly identified as “White/Caucasian” and of
higher socio-economic status; not being the groups
conventionally considered as being highest risk for de-
veloping NCDs. Further research to determine whether
the findings are also applicable in groups commonly
considered of higher-risk and also research to follow-up
patients to determine how many go on to receive formal
diagnosis and onward management is needed to under-
stand the true potential impact of risk-assessment for
NCDs in these settings.
The main challenges associated with the study include
the sample size employed, this was small as the purpose
of the study was to demonstrate patient acceptability
and potential barriers prior to undertaking a formal
feasibility study for a definitive trial. The study was not-
representative of the population with almost 100% of
participants identifying themselves as white/Caucasian.
Whilst we demonstrated that testing in these locations
can be undertaken to good effect when a dedicated
member of staff is undertaking the risk-assessment
process, this may not be possible in everyday practice
where an additional staff member may not always be
available. In the pharmacy and dental settings, the add-
itional service was logistically challenging alongside trad-
itional duties when no additional staff were available to
undertake the risk-assessments associated with the
study. Additionally, securing funding at the individual
pharmacy and dental practice to provide such services
could act as a barrier. Further work is needed to demon-
strate that this can be done by the existing team within
each setting and to demonstrate the cost-effectiveness of
the risk-assessment process should an additional dedi-
cated member of staff be required.
To our knowledge this method of risk-assessing for
multiple NCDs in a dental setting has not previously
been undertaken. Utilising dental settings to test for
T2DM has been demonstrated to good effect outside of
the UK and this study further supports those findings
[23–27]. We also demonstrated the advantage of a 2-
step risk-assessment process for T2DM which is
supported by the study of Bould et al. [28]. Similarly, in
a pharmacy setting isolated small-scale pilot initiatives
have shown promising results, but nationally POCT and
risk assessment for multiple NCDs is not standard prac-
tice. Although small initiatives for screening for NCDs
have been undertaken in UK pharmacies, besides the
NHS Health Check (which is a health check-up designed
to spot early signs of kidney disease, heart disease and
type 2 diabetes) and The Healthy Living Pharmacies
(HLPs) initiative very few services in UK pharmacies
have been consistent. This is despite these being part of
the NHS Long Term Plan, therefore, this study could
add to the existing evidence and support prevention
roles for pharmacists [29, 30].
NICE currently recommends that allied healthcare
professionals, including community pharmacists and
general dental practitioners [GDPs], should risk-assess
for T2DM [31]. To the authors knowledge this is not
currently undertaken in general dental practice nor is it
routine practice in community pharmacies at a national
level. Furthermore, the feasibility of such risk-
assessments has yet to been determined. Our study
provides the groundwork for investigating this further,
having determined a positive response from patients
accessing these services and that the potential devices
required to undertake the risk-assessments perform well.
This study demonstrated strong support from partici-
pants for the use of allied healthcare professionals to
provide targeted risk-assessments for NCDs. It also dem-
onstrated that the methods required to undertake such
assessments were acceptable to participants.
However, the concept of dentists and pharmacists test-
ing for NCDs is not without controversy. Firstly, the UK
National Screening Committee clearly states that it does
not support population-based screening for NCDs [32].
Though evidence suggests a population-based screening
programme lacks benefit, the potential benefits of an op-
portunistic risk-directed assessment of patients who
have risk-factors for NCDs, and who may not have had
contact with another healthcare professional in the pro-
ceeding 12months is yet to be determined. Opticians
currently identify potential signs of CVD and T2DM and
advise patients to seek GP follow-up and refer patients
to their GP for formal assessment. The present study
provides insights into the potential for a similar ap-
proach in high street dental surgeries and community
pharmacies. Further work is needed to determine feasi-
bility of such a model within the UK healthcare system
to assess both the effectiveness and cost-effectiveness of
such a strategy and to ensure suitable care pathways for
those patients identified with new cases of disease are
accessible.
Before further larger scale studies can be undertaken
to determine cost-effectiveness and clinical effectiveness
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of undertaking such targeted risk assessment’s in dental
and pharmacy settings, careful consideration must be
given to the patient’s care pathway following identifica-
tion of a previously unknown elevated risk status. More-
over, care must be taken to avoid duplicated testing as
many patients may have already undergone a NHS
Health-check with their GP in the previous 12months.
In addition, care and consideration is required to pre-
vent adding to the ever-growing burden on GPs by in-
creased referral loads without consideration of how
these patients should be managed and how the add-
itional referrals will be funded. Further work is needed
to determine what the additional burden to Primary
Care services could be and to mitigate for this, whilst
also assessing the health economic impact of such an
approach.
Conclusion
Although there is controversy surrounding the precision
and accuracy of POCT, the devices tested in this study
demonstrated good levels of concordance with standard
laboratory methods and may present a viable alternative
to laboratory-based methods when risk-assessing
patients for NCDs in community settings. Participant ac-
ceptability to finger-prick testing was positive. Further
work is required to determine whether testing for NCDs
in a dental practice and pharmacy setting is feasible in
terms of logistics, environment and process. Based on
this work it appears that to minimise the negative im-
pact on day-to-day running of current services additional
dedicated staff may be required to undertake the risk-
assessment in dental and pharmacy settings. Further
work also needs to be undertaken with suitable follow
up to determine whether there are health and economic
benefits to such a model.
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